Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium tc 99m succimer (ROTOP Pharmaka)
- Development stage
- Unknown
- Lead developer
- ROTOP Pharmaka
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Technetium Tc 99m dimercaptosuccinic acid (also known as technetium Tc 99m succimer or Tc-99m DMSA) is a diagnostic radiopharmaceutical used as an imaging agent for renal cortical scintigraphy. It is primarily indicated as an aid in the scintigraphic evaluation of renal parenchymal disorders in both adult and pediatric patients, including term neonates. Following intravenous administration, the tracer binds to plasma proteins (such as alpha-1-microglobulin) and is filtered by the glomeruli, after which it is accumulated in the proximal renal tubular cells of the renal cortex via megalin/cubilin-mediated endocytosis. This allows for high-resolution static imaging of the renal parenchyma to assess renal structure, morphology, split renal function, and to detect cortical scarring or pyelonephritis.
- Brand names
- MPI DMSANephroScanTechnemekTechnescan DMSA
- Other names
- 99mTc-DMSA99mTc-dimercaptosuccinic acid99mTc-succimerTc-99m DMSATc99m DMSATc 99m DMSAtechnetium (99mTc) succimertechnetium Tc 99m DMSAtechnetium Tc 99m dimercaptosuccinic acidtechnetium-99m dimercaptosuccinic acidtechnetium99m dimercaptosuccinic acidtechnetium 99m dimercaptosuccinic acidtechnetium-99m succimertechnetium99m succimertechnetium 99m succimer
02
Targets
AMBP (Alpha-1-microglobulin)A2M (Alpha-2-macroglobulin)
Beyond the preview
Go deeper on technetium tc 99m succimer (ROTOP Pharmaka).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium tc 99m succimer (ROTOP Pharmaka).